The Time is Now: Philip, a Koselugo Success Story for Neurofibromatosis Type 1 (NF1) скачать в хорошем качестве

The Time is Now: Philip, a Koselugo Success Story for Neurofibromatosis Type 1 (NF1)

Thanks to groundbreaking research funded by our generous donors, there are now FDA-approved treatment options for neurofibromatosis and schwannomatosis, with even more promising therapies on the horizon. Explore how innovation is transforming care for those living with NF and schwannomatosis. Subscribe, and click the bell, for more NF stories & research updates:    / @childrenstumor   Donate today at https://www.ctf.org/ways-to-give/ Visit our website at https://www.ctf.org/ What is the Children's Tumor Foundation? The Children’s Tumor Foundation (CTF) is the drug discovery engine for NF. Everything we do is to bring treatments to patients as we work toward a cure. By connecting patients, doctors, scientists, and pharma, we drive treatments, advance care, and deliver results for millions affected by neurofibromatosis or schwannomatosis, collectively referred to as NF. Our patient-first collaborative approach accelerates drug development and brings life-changing therapies to patients faster, driven by our mission to end NF. About NF: NF refers to a group of genetic conditions that cause tumors to grow on nerves throughout the body. NF affects 1 in 2,000 births and may lead to blindness, deafness, bone abnormalities, disfigurement, learning disabilities, disabling pain, or cancer. NF affects all races, ethnic groups, and genders equally. The types of NF include neurofibromatosis type 1 (NF1) and all types of schwannomatosis (SWN), including NF2-related schwannomatosis (NF2-SWN), formerly called neurofibromatosis type 2 (NF2). Follow us on our social media platforms: Facebook -   / childrenstumor   Instagram -   / childrenstumor   Twitter -   / childrenstumor   LinkedIn -   / children's-tumor-foundation